Checkpoint inhibitors in breast cancer–current status

A Polk, IM Svane, M Andersson, D Nielsen - Cancer treatment reviews, 2018 - Elsevier
Introduction An increasing number of compounds directed against immune checkpoints are
currently under clinical development. In this review we summarize current research in breast …
被引用次数：157 相关文章

Checkpoint inhibitors in breast cancer-Current status.

A Polk, IM Svane, M Andersson… - Cancer Treatment …, 2017 - europepmc.org
Results The obtained overall response rate of PD-1/PD-L1 monotherapy varied from 5 to
30% in heavily pretreated triple negative breast cancer (TNBC). The median duration of …

Checkpoint inhibitors in breast cancer-Current status

A Polk, IM Svane, M Andersson… - Cancer treatment …, 2018 - pubmed.ncbi.nlm.nih.gov
Introduction An increasing number of compounds directed against immune checkpoints are
currently under clinical development. In this review we summarize current research in breast …

Checkpoint inhibitors in breast cancer–Current status

A Polk, IM Svane, M Andersson… - Cancer Treatment …, 2018 - cancertreatmentreviews.com
Introduction An increasing number of compounds directed against immune checkpoints are
currently under clinical development. In this review we summarize current research in breast …

[引用][C] Checkpoint inhibitors in breast cancer–Current status

A Polk, IM Svane, M Andersson, D Nielsen - Cancer Treatment Reviews, 2018 - cir.nii.ac.jp
Checkpoint inhibitors in breast cancer – Current status | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …

Checkpoint inhibitors in breast cancer-Current status

A Polk, IM Svane, M Andersson… - Evidence-based …, 2017 - research.regionh.dk
INTRODUCTION: An increasing number of compounds directed against immune
checkpoints are currently under clinical development. In this review we summarize current …